Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul;195(7):691-692.
doi: 10.1007/s00066-019-01456-3.

[Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC]

[Article in German]
Martin Wilhelm  1
Affiliations
Comment

[Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC]

[Article in German]
Martin Wilhelm. Strahlenther Onkol. 2019 Jul.
No abstract available

PubMed Disclaimer

Comment on

  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Clinical Trial.

References

    1. N Engl J Med. 2017 Nov 16;377(20):1919-1929 - PubMed
    1. World J Clin Oncol. 2017 Feb 10;8(1):1-20 - PubMed
    1. J Clin Invest. 2014 Feb;124(2):687-95 - PubMed
    1. N Engl J Med. 2018 Dec 13;379(24):2342-2350 - PubMed
    1. Lancet Oncol. 2014 Jan;15(1):59-68 - PubMed

LinkOut - more resources